Written by the Nuvirox Research Team
Key points
- The NADPARK trial found that nicotinamide riboside significantly raised brain NAD+ levels in newly diagnosed Parkinson's patients and was associated with mild clinical improvement.
- A follow-up safety trial (NR-SAFE) tested doses up to 3,000 mg/day and found NR well tolerated, supporting larger dose-optimization trials now underway.
- This is genuinely one of the most actively researched conditions in NAD+ science — and also squarely a neurology-managed condition, not a self-directed supplement decision.
Short answer: yes, there is real phase I human trial data here, more than for almost any other condition covered in this series — and it's exactly why this deserves your neurologist's input, not a supplement aisle decision.
Why would NAD+ matter for Parkinson's disease?
Parkinson's disease involves progressive loss of dopamine-producing neurons, and mitochondrial dysfunction is considered a central driver of that neurodegeneration. NAD+ is essential for mitochondrial energy production and for the DNA repair and stress-response systems that protect neurons from the toxic buildup implicated in PD. Because NAD+ levels decline with age and appear to decline further in PD, replenishing NAD+ via precursors like nicotinamide riboside has become one of the more actively pursued disease-modification strategies in PD research over the past several years.
What does the human trial evidence actually show?
The landmark NADPARK study (2022) was a double-blinded phase I trial in 30 newly diagnosed, treatment-naive PD patients, randomized to 1,000 mg NR or placebo daily for 30 days. NR treatment significantly raised cerebral NAD+ levels, measured directly via phosphorous magnetic resonance spectroscopy in the cerebrospinal fluid, and patients showing this brain NAD+ increase also showed altered cerebral glucose metabolism (via PET imaging) associated with mild clinical improvement, driven mainly by two subsections of the standard PD rating scale (MDS-UPDRS).
Study snapshot: NADPARK trial
| Design | Double-blind, randomized, placebo-controlled phase I |
| N | 30 newly diagnosed, treatment-naive PD patients |
| Dose/duration | 1,000 mg NR daily, 30 days |
| Finding | Significant rise in cerebral NAD+ (31P-MRS); mild clinical improvement associated with responders |
A follow-up safety trial, NR-SAFE, tested much higher doses — 1,500 mg twice daily (3,000 mg/day total) — in 20 PD patients over four weeks and found no moderate or severe adverse events, with blood NAD+ metabolome rising up to 5-fold. This safety data supported moving forward into larger dose-optimization studies (N-DOSE, currently recruiting 80 patients) and a much larger 400-participant trial (NOPARK) that is underway to test actual disease-modifying efficacy.
The honest counterweight
Both completed human trials so far are phase I studies — designed primarily to test safety and whether NR reaches the brain and raises NAD+, not definitively whether it slows disease progression. The "mild clinical improvement" observed in NADPARK was a secondary finding in a very small, short (30-day) trial, and the authors themselves note it may partly reflect the shorter interval since participants' last levodopa dose rather than a true NR effect. The larger, longer trials designed to actually answer the efficacy question (NOPARK, N-DOSE) are still ongoing as of this writing.
When to see a doctor
Parkinson's disease requires ongoing neurological management, and treatment decisions (including whether to explore participation in trials like NOPARK) should be made with your neurologist, who can weigh interactions with your current medications, particularly levodopa timing, which appears to matter for how these trials are interpreted.
What's actually proven to help
Levodopa and other dopaminergic therapies remain the evidence-based foundation of PD symptom management, alongside physical therapy, exercise (which has some of the strongest non-pharmacological evidence for PD), and increasingly, deep brain stimulation for appropriate candidates with advancing disease.
How does this fit with broader NAD+ and brain-aging research?
Parkinson's research sits within a larger body of work on NAD+ and neurological aging, including our coverage of whether NAD+ actually declines with age and the DNA-repair mechanisms discussed in NAD+ and DNA repair, both directly relevant to the neuroprotective rationale researchers are testing in PD. It's also worth understanding how nicotinamide riboside itself has been characterized more broadly in our overview of what nicotinamide riboside is and how it works, since the same molecule tested in NADPARK is the active ingredient in most over-the-counter NR supplements, even though the trial dose, monitoring, and clinical context differ substantially from typical supplement use.
A separate but related trial thread worth flagging: a phase 2a trial of high-dose oral nicotinamide (a related but distinct NAD+ precursor, dosed at 1,500 mg twice daily) specifically for early Alzheimer's disease found the treatment reached the brain in some but not all participants, and did not significantly lower its primary biomarker endpoint (CSF pTau231), though it did show good safety and tolerability. This is a useful comparison point: even within the same general "boost brain NAD+ in neurodegenerative disease" research strategy, results vary meaningfully by specific disease, precursor molecule, and endpoint measured — a reminder against generalizing findings across different neurodegenerative conditions.
One more detail worth understanding about NADPARK: the "mild clinical improvement" was driven mainly by two specific subsections of the MDS-UPDRS rating scale, not uniform improvement across all measured symptoms, and the authors were careful to note this was confounded by time since the last levodopa dose. That level of transparency about a study's own limitations is a good sign of research quality, and it's part of why the follow-up trials (NOPARK, N-DOSE) were designed to more rigorously separate a true NR effect from confounding factors like medication timing.
If you or a family member has Parkinson's and are interested in the ongoing NOPARK or N-DOSE trials specifically, ask your neurologist whether you're a candidate; recruitment for large multi-site trials like these often has specific eligibility windows (disease stage, medication status, imaging requirements) that a treating neurologist can help evaluate more precisely than general online information can.
Frequently asked questions
Is there real human trial data on NAD+ and Parkinson's?
Yes — NADPARK and NR-SAFE are both completed phase I human trials, with larger trials (NOPARK, N-DOSE) now underway to test whether NR actually slows disease progression.
Does this mean NR supplements treat Parkinson's?
Not yet established. The completed trials focused on safety and whether NR reaches brain NAD+; the trials designed to answer the disease-modification question are still ongoing.
Should someone with Parkinson's take an NAD+ supplement now?
This is worth discussing directly with a neurologist, given the ongoing trials and the potential relevance of medication timing to how any effects are interpreted.
From Nuvirox
Why we formulated NAD+ Restore
To be direct: NAD+ Restore is a general wellness supplement, not a treatment for this condition, and it shouldn't be used as a substitute for medical care. If you're separately interested in cellular energy support once your care team is in the loop, here's what's in it.
- 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials
- 150 mg trans-resveratrol (Japanese Knotweed) + 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support
- 10 mg galactomannans from fenugreek — to support absorption
- 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should
The bottom line: Parkinson's disease is one of the most seriously and directly studied conditions in NAD+ precursor research, with genuine phase I human trials behind it — and larger trials are actively testing whether that translates into real disease-modifying benefit. That's a reason for cautious optimism and continued attention, not a reason to substitute a supplement for neurological care.
References
- Brakedal B, et al. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metab. 2022;34(3):396-407. PMID: 35235774.
- NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease. PMCID: PMC10684646.
- N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease. ClinicalTrials.gov NCT05589766.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.